Using our science for global health

We are one of the few companies researching treatments and vaccines for all three diseases - TB, malaria and HIV- which are called out in the UN Sustainable Development Goals.

Woman with baby in Tanzania


Tuberculosis (TB) is one of the top ten causes of deaths worldwide. In 2017 alone, there were 10 million cases of TB, with 1.6 million deaths from TB, including 230,000 children.

Working with scientific and NGO partners we are developing a pipeline of potential first in class medicines and a much-needed candidate vaccine to help fight TB. With IAVI and other partners, we are finalising a Phase IIb study for the candidate vaccine, involving more than 3,500 participants in 3 African countries. We are also a founding member of the TB Drug Accelerator, a discovery consortium aimed at speeding up the discovery and development of novel compounds against TB.


There are currently 1.8 million children under 15 living with HIV - the burden of HIV in infants and children is highest in developing countries.

Through?ViiV Healthcare, we are researching new treatments for people living with HIV around the world. In a pioneering partnership with CHAI, Unitaid and two generic partners, we are working to accelerate the development and availability of optimal HIV treatments for children and adolescents. Find out more.

Millani Chhabra and Nancie Hergert working in our HIV Cure Centre, USA
Millani Chhabra and Nancie Hergert working in our HIV Cure Centre, USA


Around 400,000 people die from malaria every year, mostly children and pregnant women. Fighting malaria is hugely complex and challenging as there many different species of malaria. The most common types of malaria are Plasmodium falciparum; most prevalent in Sub Saharan Africa and Plasmodium?vivax malaria, most prevalent in South East Asia.

After more than 30 years, working in collaboration with PATH and others we have developed the first vaccine showing efficacy against the deadliest form of malaria. WHO-led pilot implementation programmes are expected to?begin in 2019 in selected regions of Ghana, Kenya and Malawi. Funded by Gavi, the Global Fund and Unitaid, they are expected to last 3-5 years. GSK has committed to donate up to 10m doses of the vaccine for the WHO pilot implementation programmes.

With Medicines for Malaria Venture we have also developed the first single-dose medicine, tafenoquine, to treat relapsing malaria. We will work with partners to provide tafenoquine at an affordable price in endemic countries, to maximise access to those who need it most, as part of global efforts to eradicate malaria.

Early discovery

Beyond HIV, TB and malaria we continue to pursue the most promising scientific leads in global health research, particularly in neglected tropical diseases (NTDs). NTDs affect more than one billion people in some of the world’s poorest communities. They cause disability, disfiguration and death, they stretch healthcare budgets and they severely constrain development opportunities.

Our Vaccines Global Health Institute based in Siena has over 40 scientists researching Shigella, invasive nontyphoidal salmonella, typhoid and paratyphoid fever, and Group A streptococcus.

And our Global Health Pharma R&D unit in Tres Cantos has over 100 scientists working on potential new medicines for TB and malaria, alongside research into a number of NTDs such as kinetoplastid diseases and causes of childhood diarrhoea.

Eva, Scientist
Scientist at Tres Cantos, Spain

As founders of the Tres Cantos Open Lab Foundation, we support scientists from around the world to join us at our Tres Cantos R&D campus and, as part of an integrated team, access our compound library, screening tools, models of disease and expertise to research diseases predominantly affecting the developing world. GSK has to date donated £20 million to the Foundation, supporting 65 research projects with over 75 different scientists.